SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin
- 1 October 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 190 (4), 1200-1204
- https://doi.org/10.1016/j.juro.2013.04.031
Abstract
Purpose: Prior phase II studies of intravesical gemcitabine have shown it to be active and well tolerated, but durable responses in patients with nonmuscle invasive bladder cancer who have experien...Keywords
This publication has 14 references indexed in Scilit:
- Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, 2007
- Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared with Short-Term Intravesical Chemotherapy and Short-Term Therapy with Bacillus Calmette-Guérin (BCG) in Patients with Non–Muscle-Invasive Bladder CarcinomaEuropean Urology, 2007
- Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guérin–Refractory Transitional Cell Carcinoma of the BladderJournal of Clinical Oncology, 2006
- Management of BCG Failures in Superficial Bladder Cancer: A ReviewEuropean Urology, 2006
- Randomized Phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladderUrology, 2005
- Phase II Study to Investigate the Ablative Efficacy of Intravesical Administration of Gemcitabine in Intermediate-Risk Superficial Bladder Cancer (SBC)European Urology, 2004
- Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluationBJU International, 2004
- Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic StudyJournal of Clinical Oncology, 2003
- Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the BladderJournal of Clinical Oncology, 2002
- Planned versus attained design in phase II clinical trialsStatistics in Medicine, 1992